EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients

Thomas Durand, Sophie Jacob, Laura Lebouil, Hassen Douzane, Philippe Lestaevel, Amithys Rahimian, Dimitri Psimaras, Loïc Feuvret, Delphine Leclercq, Bruno Brochet, Radia Tamarat, Fabien Milliat, Marc Benderitter, Nicolas Vayatis, Georges Noël, Khê Hoang-Xuan, Jean-Yves Delattre, Damien Ricard, Marie-Odile Bernier, Thomas Durand, Sophie Jacob, Laura Lebouil, Hassen Douzane, Philippe Lestaevel, Amithys Rahimian, Dimitri Psimaras, Loïc Feuvret, Delphine Leclercq, Bruno Brochet, Radia Tamarat, Fabien Milliat, Marc Benderitter, Nicolas Vayatis, Georges Noël, Khê Hoang-Xuan, Jean-Yves Delattre, Damien Ricard, Marie-Odile Bernier

Abstract

Background: Radiotherapy is one of the most important treatments of primary and metastatic brain tumors. Unfortunately, it can involve moderate to severe complications among which leukoencephalopathy is very frequent and implies cognitive deficits such as memory, attention and executive dysfunctions. However, the incidence of this complication is not well established and the risk factors and process are poorly understood. The main objective of the study is to improve knowledge on radio-induced leukoencephalopathy based on pluridisciplinar approaches combining cognitive, biologic, imagery and dosimetric investigations.

Method/design: The EpiBrainRad study is a prospective cohort study including newly diagnosed high grade gliomas patients treated by radiotherapy and concomitant-adjuvant temozolomide chemotherapy. Patients are included between their surgery and first day of radio-chemotherapy, and the follow-up lasts for 3 years after treatment. Cognitive functioning assessments, specific blood biomarkers measures and magnetic resonance imagery are performed at different moment during the follow-up, and a specific dosimetric assessment of organs involved in the beam fields is performed. Firstly, leukoencephalopathy incidence rate will be estimated in this population. Secondly, correlations between cognitive impairments and dosimetry, biomarkers ranges and anomalies on imagery will be analyzed in order to better understand the onset and evolution of cognitive decrement associated with radiotherapy. Furthermore, a new cognitive test, quickly and easily performed, will be studied to determine its sensibility to detect leukoencephalopathy decrement.

Discussion: With an original multidisciplinary approach, the EpiBrainRad study aims to improve knowledge on radio-induced leukoencephalopathy in order to improve its early diagnosis and prevention. The main challenge is to preserve quality-of-life after cancer treatments which imply to study the incidence of radiation-induced complications and their associated risk factors.

Trial registration: NCT02544178.

Figures

Fig. 1
Fig. 1
Study procedure

References

    1. Verdecchia A, Baili P, Quaglia A, Kunkler I, Ciampichini R, Berrino F, et al. Patient survival for all cancers combined as indicator of cancer control in Europe. Eur J Public Health. 2008;18:527–32. doi: 10.1093/eurpub/ckn022.
    1. Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374:1639–51. doi: 10.1016/S0140-6736(09)61299-X.
    1. Li J, Bentzen SM, Li J, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastases. Int J Radiat Oncol Biol Phys. 2008;71:64–70. doi: 10.1016/j.ijrobp.2007.09.059.
    1. Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin RC. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys. 2003;55:992–9. doi: 10.1016/S0360-3016(02)04205-0.
    1. Dirven L, Aaronson N, Heimans JJ, Taphoorn MJ. Health-related quality of life in high grade glioma patient. Chin J Cancer. 2014;33:40–45. doi: 10.5732/cjc.013.10214.
    1. Meyer CA, Rock EP, Fine HA. Refining endpoints in brain tumors clinical trials. J Neurooncol. 2012;108:227–30. doi: 10.1007/s11060-012-0813-8.
    1. Froklage FE, Oosterbaan LJ, Sizoo EM, de Groot M, Bosma I, Sanchez E, et al. Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study. J Neurooncol. 2014;116:387–94. doi: 10.1007/s11060-013-1310-4.
    1. Habets EJJ, Taphoorn MJB, Nederend S, Klein M, Delgadillo D, Hoang-Xuan K, et al. Health-related quality-of-life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. J Neurooncol. 2014;116:161–8. doi: 10.1007/s11060-013-1278-0.
    1. Saad S, Wang TJ. Neurocognitive deficits after radiation therapy for brain malignancies. Am J Clin Oncol. 2014. [Epub ahead of print].
    1. Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–18. doi: 10.1016/S1474-4422(09)70204-2.
    1. Hottinger AF, Yoon H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors. J Neurooncol. 2009;95:301–5. doi: 10.1007/s11060-009-9946-9.
    1. Scoccianti S, Detti B, Cipressi S, Iannalfi A, Franzese C, Biti G. Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy. J Neurooncol. 2012;108:291–308. doi: 10.1007/s11060-012-0821-8.
    1. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360:1361–8. doi: 10.1016/S0140-6736(02)11398-5.
    1. Armstrong CL, Hunter JV, Ledakis GE, Cohen B, Tallent EM, Goldstein BH, et al. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology. 2002;59:40–8. doi: 10.1212/WNL.59.1.40.
    1. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long- term survivors with malignant astrocytomas. Ann Neurol. 1990;28:818–22. doi: 10.1002/ana.410280614.
    1. Vigliani M, Duyckaerts C, Delattre J, et al. Radiation-induced cognitive dysfunction in adults. In: Vecht C, et al., editors. Handbook of clinical neurology. Amsterdam: Elsevier Science; 1997. pp. 371–88.
    1. Astrand R, Undén J, Romner B. Clinical use of the calcium-binding S100B protein. Methods Mol Biol. 2013;963:373–84. doi: 10.1007/978-1-62703-230-8_23.
    1. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer’s disease. Arch Neurol. 2002;59:972–6. doi: 10.1001/archneur.59.6.972.
    1. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Hyperhomocysteinemia associated with poor recall in the third national health and nutrition examination survey. Am J Clin Nutr. 2001;73:927–33.
    1. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013;14(7):R78. doi: 10.1186/gb-2013-14-7-r78.
    1. Xue S, Cai X, Li W, Zhang Z, Dong W, Hui G. Elevated plasma endothelial microparticules in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;34:174–80. doi: 10.1159/000343491.
    1. Ruet A, Deloire MS, Charré-Morin J, Hamel D, Brochet B. A new computerised cognitive test for the detection of information processing speed impairment in multiple sclerosis. Mult Scler. 2013;19:1665–72. doi: 10.1177/1352458513480251.
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. doi: 10.1056/NEJMoa043330.
    1. Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patient with glioblastoma: a prospective randomized controlled trial. J Clin Oncol. 2004;22:1583–8. doi: 10.1200/JCO.2004.06.082.
    1. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28:1963–72. doi: 10.1200/JCO.2009.26.3541.
    1. Wahlund LO, Barkhof F, Fazekas L, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22. doi: 10.1161/01.STR.32.6.1318.
    1. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36:268–72. doi: 10.1159/000117270.
    1. Maccioni RB, Lavados M, Maccioni CB, Mendoza-Naranjo A. Biological markers of Alzheimer’s disease and mild cognitive impairment. Curr Alzheimer Res. 2004;1:307–14. doi: 10.2174/1567205043332018.
    1. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, et al. Toward the bloodborne miRNome of human diseases. Nat Methods. 2011;8:841–3. doi: 10.1038/nmeth.1682.
    1. Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F, et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol. 2012;72:610–24. doi: 10.1002/ana.23627.
    1. Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2012;85:348–54. doi: 10.1016/j.ijrobp.2012.11.031.
    1. Peiffer AM, Leyrer CM, Greene-Schloesser DM. Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline. Neurology. 2013;80:747–753. doi: 10.1212/WNL.0b013e318283bb0a.
    1. Moore HC. An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain’. Oncology. 2014;28:797–804.
    1. Hermelink K, Küchenhoff H, Untch M, Bauerfeind I, Lux MP, Bühner M, et al. Two different sides of ‘chemobrain’: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology. 2010;19:1321–8. doi: 10.1002/pon.1695.
    1. Schagen SB, Boogerd W, Muller MJ, Huinink WT, Moonen L, Meinhardt W, et al. Cognitive complaints and cognitive impairments following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 2008;47:63–70. doi: 10.1080/02841860701518058.
    1. Taillia H, Bompaire F, Jacob J, Noël G. Cognitive evaluation during brain radiotherapy in adults: a simple assessment is possible. Cancer Radiother. 2013;17:413–8. doi: 10.1016/j.canrad.2013.07.139.
    1. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumors in adults. Lancet. 2012;379:1984–96. doi: 10.1016/S0140-6736(11)61346-9.
    1. Mackinnon A, Mullingan R. Estimation de l’intelligence prémorbide chez les francophones. Encéphale. 2005;31:31–43. doi: 10.1016/S0013-7006(05)82370-X.
    1. Kalafat M, Hugonot-Diener L, Poitrenaud J. Standardisation et étalonnage français du “Mini Mental State” (MMS) version GRECO. Rev Neuropsychol. 2003;13:209–36.
    1. Nasreddine Z, Phillips N, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment (moca): a brief screening tool for middle cognitive impairment. J Am Ger Soc. 2005;53:695–99. doi: 10.1111/j.1532-5415.2005.53221.x.
    1. Mattis M. Dementia Rating Scale-2. Lutz: Psychological assessment resource. Inc; 2001.
    1. Van Der Linden M, Coyette F, Poitrenaud J, Kalafat M, Calicis F, Wyns C, et al. L’épreuve du rappel libre/rappel indicé à 16 items (RL/RI-16). L’évaluation des troubles de la mémoire. Marseille: Editions Solal; 2004. p. 85–101.
    1. Rey A. L’examen psychologique dans les cas d’encéphalopathie traumatique. Arch Psychol. 1941;8:286–340.
    1. Wechsler D. Echelle d’intelligence de Wechsler pour adultes – 3e edition ECPA. 2000.
    1. Meulmans T. La batterie GREFEX. In: Fonctions executives et pathologies neurologiques et psychiatriques. Godefroy et GREFEX, éditeurs. Marseille, Solal; 2008. p. 217–29.
    1. Roussel M, Godefroy O. La batterie GREFEX: données normative Godefroy O et GREFEX, éditeurs. Marseille, Solal; 2008. p. 217–29.
    1. Tuillard-Colombo F, Assal G. Boston Naming Test: French-language adaptation and short forms. Eurn Rev Appl Psychol. 1992;42:67–73.
    1. De Renzi E, Faglioni P. Normative data and screening power of a shortened version of the Token Test. Cortex. 1978;14:41–49. doi: 10.1016/S0010-9452(78)80006-9.
    1. Goldberg D, Bridges K, Duncun-Jones P, Grayson D. Detecting anxiety and depression in general medical setting. BMJ. 1988;297:897–9. doi: 10.1136/bmj.297.6653.897.
    1. Furher R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Study Depression Scale). Description et traduction de l’échelle d’auto-évaluation. Psychiat Psychobiol. 1989;4:163–66.
    1. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the functional assessment of chronic illness therapy fatigue relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811–9.
    1. McNair DM, Kahn RJ. Self assessment of cognitive deficit. In: Crook Th. And Coll. Assessment in geriatric psychopharmacology. Mark Powley Associates Ed, New Canaan-Connecticut; 1983. p. 137–43.
    1. Poitrenaud J, Israel L, Barrere H, le Roc’h. Version française de l’échelle de difficulties cognitive de Mac-Nair et Khan. In: de la plainte mnésique à la maladie d’Alzheimer. Michel BF, Derouesne C, Gely-Nargeot MC, Eds. Marseille, Solal; 1997.
    1. Mac Lachlan S, Devins G, Goodwin P. Validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer. 1998;34:510–7. doi: 10.1016/S0959-8049(97)10076-4.
    1. Taphoorn MJ, Claasens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46:1033–40. doi: 10.1016/j.ejca.2010.01.012.
    1. Israel L. L’IADL. In: L’évaluation Clinique standardisée en psychitrie (tome 2). Guelfi, Ed. Editions médicales Pierre Fabre, 1996. p. 477–80.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner